AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants with advanced or metastatic solid tumors harboring KRAS alterations. This is a dose-escalation study in which participants will be assigned to multiple dose levels (DLs) of AMG 410, either as monotherapy or in combination with other agents, followed by expansion cohorts. The goal is to determine the Maximum Tolerated Dose (MTD)-the highest dose with acceptable safety and manageable side effects-or the Recommended Phase 2 Dose (RP2D) of AMG 410 in adult participants with KRAS-altered advanced or metastatic solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Zaawansowany nowotwór ze zmianami w genie KRAS potwierdzonymi badaniem
- •Brak dostępnych standardowych opcji leczenia lub pacjent je odrzucił
- •Możliwość połykania leku w postaci tabletkek
- •Dobry stan ogólny (zdolny do codziennych aktywności)
- •Możliwość zmierzenia wielkości nowotworu w badaniach obrazowych
- •Prawidłowe funkcjonowanie narządów wewnętrznych
- •Dostępne wcześniejsze próbki tkanki nowotworowej lub możliwość ich pobrania
✗ Disqualifies
- •Przerzuty do mózgu lub opon mózgowych bez leczenia
- •Niekontrolowany płyn w płucach lub jamie brzusznej
- •Inny nowotwór w ostatnich 5 latach
- •Aktywna infekcja wymagająca antybiotyków
- •Historia zakrzepów krwi (udar, zawał płucny)
- •Szczepienia żywą wakcyną w ciągu 4 tygodni przed badaniem
- •Historia przeszczepu narządu
- •Wcześniejsze leczenie onkologiczne w ciągu 28 dni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (38)
City of Hope National Medical Center
Duarte, United States
University of California Los Angeles
Los Angeles, United States
Emory University
Atlanta, United States
Massachusetts General Hospital
Boston, United States
Siteman Cancer Center - Washington University
St Louis, United States
Duke Cancer Center
Durham, United States
Thomas Jefferson University
Philadelphia, United States
Sarah Cannon Research Institute Oncology Partners
Nashville, United States
Next Oncology
San Antonio, United States
Next Virginia
Fairfax, United States
Chris OBrien Lifehouse
Camperdown, Australia
The Queen Elizabeth Hospital
Woodville South, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Princess Margaret Cancer Centre
Toronto, Canada
Sir Mortimer B Davis - Jewish General Hospital
Montreal, Canada
Beijing Cancer Hospital
Beijing, China
Chongqing University Cancer Hospital
Chongqing, China
Jinan Central Hospital
Jinan, China
Rigshospitalet
Copenhagen, Denmark
Centre Leon Berard
Lyon, France
Gustave Roussy
Villejuif, France
Universitaetsklinikum Essen
Essen, Germany
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
Centro Ricerche Cliniche Di Verona Societa responsabilita limitata
Verona, Italy
Aichi Cancer Center
Nagoya, Japan
National Cancer Center Hospital East
Kashiwa-shi, Japan
National Cancer Center Hospital
Chuo-ku, Japan
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Hospital Universitari Vall d Hebron
Barcelona, Spain
Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Sarah Cannon Research Institute UK
London, United Kingdom
Royal Marsden Hospital
Sutton, United Kingdom
Trial contact
Amgen Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.